echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Officials said that the current peak of fever clinics has passed the Chinese market debut of monolavir

    Officials said that the current peak of fever clinics has passed the Chinese market debut of monolavir

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "The peak of fever clinics has passed", "The peak of emergency care in the country has passed", "Normal outpatient diagnosis and treatment is gradually recovering".
    .
    .
    The press conference of the joint prevention and control mechanism of the State Council of China on the 14th released the above information
    .
    Just the day before, the new coronavirus oral drug monogravir capsules completed the first launch in the Chinese market and have been delivered to medical institutions
    .
    Chinese officials have also said they are studying strengthening the allocation of
    small molecule antivirals in grassroots health institutions.
    The peak of fever clinics has passed Previously, many places have announced that the peak of this round of new crown infection has passed
    .
    After the implementation of "Class B tube", what is the change trend of fever outpatient and outpatient emergency department visits in China? In response to a question from a reporter from the China News Agency at the press conference of the joint prevention and control mechanism of the State Council of China on the 14th, Jiao Yahui, director of the Department of Medical Administration of the National Health Commission, said that at present, the number of fever clinics and consultation rooms in all provinces, autonomous regions, municipalities directly under the central government and the Xinjiang Production and Construction Corps has shown an overall downward trend after peaking, rural areas have also shown a downward trend, and urban and rural areas converge.

    The proportion of new crown positive infections detected in fever clinics has also continued to decline
    .
    Jiao Yahui said that this trend indicates that the peak of fever clinics has passed
    .
    She also said that the emergency department has also shown a continuous downward trend after peaking, and the data shows that the national emergency department peak has passed
    .
    The daily volume of general outpatient consultations continues to increase, and normal medical treatment is gradually resuming
    .
    On the other hand, many places have recently released information indicating that around the Spring Festival or ushering in a small peak
    of the second wave of infection.
    "Shaoxing release" WeChat public account previously posted that with the arrival of the holiday, the flow of people is relatively intensive, rural areas ushered in a wave of people returning to their hometowns, and there may be a wave of small peaks of infection around the Spring Festival
    .
    Cai Maorong, secretary of the Party Committee of the Zhangzhou CDC in Fujian Province, said in an interview that the city is expected to usher in a second wave of infections before the Spring Festival
    .
    Wang Chunting, head of the medical treatment expert group of the Shandong Province Leading Group for the Handling of the New Crown Epidemic, also said earlier this month that the second wave of infection in Jinan will occur
    during the Spring Festival after the start of the Spring Festival on January 10.
    The number of critically ill patients in hospital remains high The treatment of critically ill patients is the top priority
    of China's epidemic prevention and control work.
    At present, the focus of prevention and control has shifted to "health care and prevention of severe disease", what is the treatment of severe cases of new crown in the country? Jiao Yahui said that monitoring data showed that two weeks after the peak of fever clinics, the number of new crown-positive severe patients in the hospital also peaked, and then showed a slow downward trend
    .
    "The number of critically ill patients currently in hospital is still at a high level"
    .
    According to reports, on January 5 this year, the number of new crown positive severe patients in hospitals in China peaked at 128,000, and then fluctuated and declined
    .
    By January 12, the number of hospital-positive critically ill patients had fallen back to 105,000
    .
    On January 12, among the new crown-positive severe patients in the hospital, 97,000 people with severe underlying diseases combined with new coronavirus infection accounted for 92.
    8%; The number of severely ill patients infected with the new coronavirus is 7,357, accounting for 7%.

    Rural areas are the focus of epidemic prevention and control efforts
    .
    From the perspective of medical treatment, the capacity of severe treatment of new crown in rural areas needs to be further improved
    .
    Jiao Yahui also mentioned that it is necessary to give full play to the leading role of county hospitals, prepare beds, equipment, facilities and personnel, and improve the ability of severe treatment; Relying on the counterpart support mechanism of urban and rural hospitals that has been formed, all urban tertiary hospitals are zoned and establish one-to-one support relationships with county hospitals; Establish support and referral mechanisms and green channels between cities and counties to ensure that critically ill patients in rural areas can be referred and admitted in a timely manner
    .
    Monoravir debuted in China According to reports, on the afternoon of January 13, a truck full of capsules of the new coronavirus treatment drug monoravir was sent out from the Shanghai Waigaoqiao Free Trade Zone and sent to the whole country
    .
    At 23:58 on the same day, Sinopharm Guangzhou Company and Sinopharm Beijing Company delivered the drugs to medical institutions respectively, completing the first delivery
    in China.
    On December 29, 2022, China's National Medical Products Administration conditionally approved the import registration
    of Monoravir capsules, Merck's new coronavirus treatment drug.
    This drug is an oral small molecule novel coronavirus treatment used to treat adult patients
    with mild to moderate novel coronavirus infection with factors at risk for progression to severe disease.
    China recently announced the tenth edition of the new crown diagnosis and treatment plan, monoravir capsules are also included
    .
    Wang Guiqiang, director of the Department of Infectious Diseases at Peking University First Hospital, recently said that antiviral therapy is an important part of comprehensive treatment, and small molecule drugs are convenient to take orally and can be used
    in community family clinics.
    Priority use is given to people at high risk of severe disease, that is, the elderly, those with underlying diseases, and those who have not been vaccinated, which can reduce the risk of
    severe disease.
    Wang Guiqiang also said that the small molecule new coronavirus treatment developed in China is in full swing for clinical trials, and if the clinical results are effective, it is expected to be approved for marketing
    as soon as possible.
    At the press conference on January 14, Jiao Yahui also said that it is currently studying to strengthen the allocation of small molecule antiviral drugs in grassroots health institutions to further improve the medical treatment capacity
    of grassroots health institutions.
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.